Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046334 | 1.00 | MEN1 (0.41) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL10046408 | 1.00 | MEN1 (0.41) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL13014692 | 1.00 | MEN1 (0.41) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL11933675 | 0.98 | EPHX2 (0.41) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL15494035 | 0.97 | MEN1 (0.41) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL7951389 | 0.93 | MEN1 (0.41) | MEN1KMT2ATSHRRECQLFAAH | |
| SCHEMBL13870366 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL10046330 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL13007887 | 0.92 | MEN1 (0.40) | MEN1KMT2AEPHX2TSHRRECQL | |
| SCHEMBL10046331 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2AEPHX2TSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530620-B2 | Radiolabelling reagents and methods | GE HEALTHCARE LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530620-B2 | Radiolabelling reagents and methods | GE HEALTHCARE LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8299030-B2 | Peptide-based compounds | GE HEALTHCARE LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120020882-A1 | PEPTIDE-BASED COMPOUNDS | GE HEALTHCARE AS (NO) | 2012-01-26 | — | — | US | disclosed |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-7972588-B2 | Radiolabelling methods | HAMMERSMITH IMANET LIMITED (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7972588-B2 | Radiolabelling methods | HAMMERSMITH IMANET LIMITED (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20110123445-A1 | TREATMENT MONITORING | GE HEALTHCARE LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-7897142-B2 | Cyclic nonapeptides coupled to a cyanine dye as an imaging contrast agent; monitoring angiogenesis inhibition | GE HEALTHCARE AS (NO) | 2011-03-01 | — | — | US | disclosed |
| US-7897142-B2 | Cyclic nonapeptides coupled to a cyanine dye as an imaging contrast agent; monitoring angiogenesis inhibition | GE HEALTHCARE AS (NO) | 2011-03-01 | — | — | US | disclosed |
| US-20100233082-A1 | 68GA-Labeled Peptide-Based Radiopharmaceuticals | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100233082-A1 | 68GA-Labeled Peptide-Based Radiopharmaceuticals | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20090311177-A1 | Radiolabelling Methods | GE HEALTHCARE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090311177-A1 | Radiolabelling Methods | GE HEALTHCARE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20080095715-A1 | Peptide Based-Compounds | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
| US-20080095715-A1 | Peptide Based-Compounds | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123445-A1 | TREATMENT MONITORING | NRAS, KRAS, BRAF | MEN1 1030/4885KMT2A 1044/4885EPHX2 2839/4885 |
| US-20100233082-A1 | 68GA-Labeled Peptide-Based Radiopharmaceuticals | ITGAV, ITGB3, GRPR | MEN1 716/4885KMT2A 3953/4885EPHX2 4219/4885 |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | ANPEP, DNPEP, QRFPR | MEN1 51/4885KMT2A 3853/4885EPHX2 2204/4885 |
| US-20080095715-A1 | Peptide Based-Compounds | TEK, FLT4, FLT1 | MEN1 649/4885KMT2A 4418/4885EPHX2 4217/4885 |
| US-20090311177-A1 | Radiolabelling Methods | CTSV, NGLY1, MAN2B1 | MEN1 26/4885KMT2A 3650/4885EPHX2 1564/4885 |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | MEN1 300/4885KMT2A 2645/4885EPHX2 142/4885 |
| US-20120020882-A1 | PEPTIDE-BASED COMPOUNDS | ITGB3, ITGAV, SELPLG | MEN1 769/4885KMT2A 4471/4885EPHX2 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.